CYP2D6 gene variants: Association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

92Citations
Citations of this article
111Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Tamoxifen is one of the most effective adjuvant breast cancer therapies available. Its metabolism involves the phase I enzyme, cytochrome P4502D6 (CYP2D6), encoded by the highly polymorphic CYP2D6 gene. CYP2D6 variants resulting in poor metabolism of tamoxifen are hypothesised to reduce its efficacy. An FDA-approved pre-treatment CYP2D6 gene testing assay is available. However, evidence from published studies evaluating CYP2D6 variants as predictive factors of tamoxifen efficacy and clinical outcome are conflicting, querying the clinical utility of CYP2D6 testing. We investigated the association of CYP2D6 variants with breast cancer specific survival (BCSS) in breast cancer patients receiving tamoxifen.Methods: This was a population based case-cohort study. We genotyped known functional variants (n = 7; minor allele frequency (MAF) > 0.01) and single nucleotide polymorphisms (SNPs) (n = 5; MAF > 0.05) tagging all known common variants (tagSNPs), in CYP2D6 in 6640 DNA samples from patients with invasive breast cancer from SEARCH (Studies of Epidemiology and Risk factors in Cancer Heredity); 3155 cases had received tamoxifen therapy. There were 312 deaths from breast cancer, in the tamoxifen treated patients, with over 18000 years of cumulative follow-up. The association between genotype and BCSS was evaluated using Cox proportional hazards regression analysis.Results: In tamoxifen treated patients, there was weak evidence that the poor-metaboliser variant, CYP2D6*6 (MAF = 0.01), was associated with decreased BCSS (P = 0.02; HR = 1.95; 95% CI = 1.12-3.40). No other variants, including CYP2D6*4 (MAF = 0.20), previously reported to be associated with poorer clinical outcomes, were associated with differences in BCSS, in either the tamoxifen or non-tamoxifen groups.Conclusions: CYP2D6*6 may affect BCSS in tamoxifen-treated patients. However, the absence of an association with survival in more frequent variants, including CYP2D6*4, questions the validity of the reported association between CYP2D6 genotype and treatment response in breast cancer. Until larger, prospective studies confirming any associations are available, routine CYP2D6 genetic testing should not be used in the clinical setting. © 2010 Abraham et al.; licensee BioMed Central Ltd.

References Powered by Scopus

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials

6882Citations
N/AReaders
Get full text

Assessing the probability that a positive report is false: An approach for molecular epidemiology studies

1522Citations
N/AReaders
Get full text

Efficiency and power in genetic association studies

1499Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

3093Citations
N/AReaders
Get full text

Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects

224Citations
N/AReaders
Get full text

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

163Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Abraham, J. E., Maranian, M. J., Driver, K. E., Platte, R., Kalmyrzaev, B., Baynes, C., … Caldas, C. (2010). CYP2D6 gene variants: Association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Research, 12(4). https://doi.org/10.1186/bcr2629

Readers over time

‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2505101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 40

62%

Researcher 11

17%

Professor / Associate Prof. 10

15%

Lecturer / Post doc 4

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 26

39%

Agricultural and Biological Sciences 16

24%

Biochemistry, Genetics and Molecular Bi... 15

22%

Pharmacology, Toxicology and Pharmaceut... 10

15%

Article Metrics

Tooltip
Mentions
References: 3

Save time finding and organizing research with Mendeley

Sign up for free
0